Dermatology and Therapy最新文献

{"title":"Determinants of Satisfaction with Medical Care for Hidradenitis Suppurativa: Results from a Multicentre Survey in Germany.","authors":"Kerstin Wolk, Dagmar Wilsmann-Theis, Nessr Abu Rached, Giorgia Cugno, Rotraut Moessner, Christian Kromer, Falk G Bechara, Katharina Assaf, Wiebke K Peitsch, Lisa C Schneider, Andreas Happ, Valentina Siddi, Diana Kubitzki, Durdana Groß, Markus Friedrich, Staffan Vandersee, Khusru Asadullah, Sylke Schneider-Burrus, Georgios Kokolakis, Robert Sabat","doi":"10.1007/s13555-025-01558-0","DOIUrl":"https://doi.org/10.1007/s13555-025-01558-0","url":null,"abstract":"<p><strong>Introduction: </strong>Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease associated with considerable physical and psychosocial distress. Recent studies have reported low levels of satisfaction among patients with HS regarding the medical care of their condition. The objective of the study was to identify modifiable determinants of low satisfaction with HS care from both patient and dermatologist perspectives.</p><p><strong>Methods: </strong>This prospective, questionnaire-based survey was conducted among patients with HS and, for comparison, among those with psoriasis, as well as their treating dermatologists, in 20 dermatological centres in Germany.</p><p><strong>Results: </strong>A total of 257 patients and 76 dermatologists participated in the study. The proportion of patients reporting high satisfaction with care for their skin disease (scores > 8 on a 0-10 scale) was 30.7% for HS and 69.4% for psoriasis (P < 0.001). The proportion of dermatologists highly satisfied with medical care for HS and psoriasis was 0.0% and 38.9%, respectively (P < 0.001). Multiple regression modelling revealed that satisfaction with pharmacotherapy was the primary predictor of medical care satisfaction for both patients and dermatologists. Experience with systemic antibiotics was associated with lower patient satisfaction regarding pharmacotherapy, while satisfaction tended to be higher when patients had experienced therapy with biologics. Another significant determinant of patient satisfaction with medical care was the provision of information about HS by dermatologists, which was linked to consultations occurring at least quarterly and lasting ≥ 20 min. No association was observed between disease severity and the identified determinants of patient satisfaction with medical care. Dermatologists' satisfaction with medical care was additionally linked with the perceived availability of referral options to other dermatological facilities.</p><p><strong>Conclusions: </strong>Improvements in patient satisfaction with HS care may be achieved through enhanced patient education about the disease and regular dermatologist consultations; however, optimal HS management ultimately requires effective pharmacological treatment.</p><p><strong>Trial registration: </strong>drks.de, DRKS00031572.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145250288","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Considerations for Treating Generalized Pustular Psoriasis (GPP): A Narrative Review.","authors":"Charles W Lynde, Vimal H Prajapati, Melinda J Gooderham, H Chih-Ho Hong, Mark G Kirchhof, Perla Lansang, Julien Ringuet, Irina Turchin, Ron Vender, Jensen Yeung, Kim A Papp","doi":"10.1007/s13555-025-01535-7","DOIUrl":"https://doi.org/10.1007/s13555-025-01535-7","url":null,"abstract":"<p><p>Generalized pustular psoriasis (GPP) is a rare, chronic dermatological condition characterized by widespread pustulation that may be associated with other cutaneous and systemic manifestations. If left untreated, it may be life-threatening. Therapies developed for plaque psoriasis have been used to treat GPP with limited efficacy; however, these therapies do not target the interleukin (IL)-36 pathway, which is the most common pathway implicated in the pathogenesis of GPP. A systemic biologic targeting the IL-36 receptor for the treatment of GPP is currently the only approved treatment for GPP and allows for an opportunity to improve patient outcomes. This manuscript outlines practical considerations that aim to provide guidance on personalizing the treatment of GPP.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-10-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145250257","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Bimekizumab Efficacy in Psoriasis by Subgroups: Post Hoc Analysis of Phase 3/3b Clinical Trials.","authors":"Bruce Strober, Wolf-Henning Boehncke, James G Krueger, Nina Magnolo, Ronald Vender, Richard B Warren, José Manuel López Pinto, Sarah Kavanagh, Bengt Hoepken, Paolo Gisondi","doi":"10.1007/s13555-025-01557-1","DOIUrl":"https://doi.org/10.1007/s13555-025-01557-1","url":null,"abstract":"&lt;p&gt;&lt;strong&gt;Introduction: &lt;/strong&gt;Patient demographics, disease characteristics, and treatment history can impact the efficacy of biologic treatments in patients with psoriasis. Understanding the efficacy of biologics, such as bimekizumab, across diverse patient subgroups is important for optimising treatment outcomes. Here, we assess whether high overall clinical responses observed in bimekizumab-treated patients with moderate to severe plaque psoriasis are consistent across subgroups, both versus comparators and with long-term treatment.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Methods: &lt;/strong&gt;Data were analysed post hoc from the BE SURE, BE VIVID, and BE READY phase 3 trials, their open-label extension (OLE) BE BRIGHT, and the BE RADIANT phase 3b trial. Patients received either bimekizumab or adalimumab to week 24 (BE SURE), bimekizumab or ustekinumab to week 52 (BE VIVID), and bimekizumab or secukinumab to week 48 (BE RADIANT). In the 3-year pooled analysis (all trials), included patients received bimekizumab continuously from baseline into the OLE. Subgroups of patients with moderate to severe plaque psoriasis were defined by age, sex, weight, disease duration, disease severity, nail involvement (modified Nail Psoriasis Severity Index &gt; 0), and prior biologic exposure, at baseline. The proportions of patients achieving complete skin clearance (PASI 100; 100% improvement from baseline in Psoriasis Area and Severity Index) in each subgroup are reported alongside 95% confidence intervals (CI). Modified non-responder imputation (mNRI) was used for missing data.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Results: &lt;/strong&gt;Following comparator-controlled periods, the proportion of bimekizumab-treated patients who achieved PASI 100 was consistent across subgroups and numerically greater versus patients who received adalimumab (to week 24), ustekinumab (to week 52), and secukinumab (to week 48) in all subgroups. Among patients who received bimekizumab continuously for 3 years (N = 1107), PASI 100 response rates remained consistent across age (68.6% [40 to &lt; 65 years]-73.7% [≥ 65 years]), sex (69.6% [male]-71.4% [female]), weight (63.4% [≥ 103.9 kg]-75.5% [&lt; 74.3 kg]), disease duration (65.5% [≤ 5 years]-71.1% [&gt; 20 years]), disease severity (67.7% [PASI 12 to &lt; 15]-71.1% [PASI ≥ 20]), nail involvement (69.1% [yes]/71.3% [no]), and prior biologic exposure (71.7% [yes]/69.1% [no]; prior anti-TNF exposure 67.6% [yes]/70.6% [no]) subgroups; 95% CIs overlapped in all instances, indicating no meaningful differences between subgroups.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Conclusion: &lt;/strong&gt;Bimekizumab demonstrated consistently high long-term efficacy in patients with psoriasis across diverse subgroups. Higher rates of PASI 100 were achieved with bimekizumab versus adalimumab, ustekinumab, and secukinumab, across all subgroups. These results highlight bimekizumab as an effective treatment for a broad range of people living with psoriasis.&lt;/p&gt;&lt;p&gt;&lt;strong&gt;Trial registration: &lt;/strong&gt;NCT03412747, NCT03370133, NCT03410992, NCT03598790","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145250275","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dermatologic Comorbidities Associated with Atopic Dermatitis Towards a Shared Therapeutical Approach: A Narrative Review.","authors":"Maria Esposito, Alessandro Giunta, Andrea De Berardinis, Lina Maria Magnanimi, Maria Concetta Fargnoli, Cataldo Patruno, Luca Potestio, Maddalena Napolitano","doi":"10.1007/s13555-025-01536-6","DOIUrl":"https://doi.org/10.1007/s13555-025-01536-6","url":null,"abstract":"<p><strong>Introduction: </strong>Atopic dermatitis (AD) is a chronic inflammatory skin condition commonly associated with other dermatologic comorbidities, which can complicate management and affect treatment outcomes. This review aims to analyse the dermatologic comorbidities of AD, their underlying mechanisms, and therapeutic implications, with a focus on their management in clinical practice.</p><p><strong>Methods: </strong>A narrative review was conducted by searching PubMed, Embase, Cochrane and ClinicalTrials.gov, using terms related to AD and its comorbidities, including allergic contact dermatitis, alopecia areata, prurigo nodularis, psoriasis, hidradenitis suppurativa and chronic spontaneous urticaria.</p><p><strong>Results: </strong>The literature highlights a strong association between AD and several dermatologic comorbidities, including allergic contact dermatitis, alopecia areata, chronic spontaneous urticaria, hidradenitis suppurativa, psoriasis, prurigo nodularis and vitiligo. Promising therapeutic effects were observed with JAK inhibitors, dupilumab and other biologics across multiple comorbid condition.</p><p><strong>Conclusion: </strong>Recognizing comorbidities in AD is critical for effective management. Tailored therapies targeting both AD and its comorbidities, based on shared immunological mechanisms, may improve outcomes. Further research is needed to optimize treatment strategies and explore combination therapies for patients with both AD and comorbid dermatological conditions.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145250235","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of IL17/23 Inhibitors on Markers of Subclinical Atherosclerosis in Patients with Psoriasis: An Observational Study.","authors":"Aikaterini Tsiogka, Stergios Soulaidopoulos, Stamatios Gregoriou, Natalia Rompoti, Pantelis Panagakis, Marina Papoutsaki, Panagiotis Kostakis, George Kontochristopoulos, Konstantinos Tsioufis, Charalambos Vlachopoulos, Alexander Stratigos, Dimitrios Rigopoulos","doi":"10.1007/s13555-025-01549-1","DOIUrl":"https://doi.org/10.1007/s13555-025-01549-1","url":null,"abstract":"<p><strong>Introduction: </strong>To date, several reports demonstrated improved markers of subclinical atherosclerosis in patients with psoriasis treated with biologics. However, data on the antiatherogenic effect of IL23 inhibitors are sparse. Herein, we sought to assess the impact of 1-year treatment with an interleukin (IL)-17 or IL-23 inhibitor on arterial stiffness in patients with moderate-to-severe psoriasis.</p><p><strong>Methods: </strong>This observational cohort study included patients with moderate-to-severe psoriasis treated with either an IL-17 inhibitor or an IL-23 inhibitor or a conventional systemic agent/apremilast (control group) for 52 weeks. The primary outcome was the evaluation of changes in carotid-femoral pulse wave velocity (PWV) and augmentation index normalized to 75 beats/min (AIx75) after 24 and 52 weeks. Secondary outcomes were the comparison of change in PWV and AIx75 between the study groups and the assessment of psoriasis disease severity scores and in ankle-brachial index (ABI).</p><p><strong>Results: </strong>In total, 66 patients (39 male/27 female), with a mean [standard deviation (SD)] age of 56 (13.1) years, were included; 21 received an IL-17 inhibitor, 29 an IL-23 inhibitor, and 16 a conventional systemic agent or apremilast (control group). PWV and AIx75 improved in all groups at weeks 24 and 52. However, a statistically significant reduction of PWV was observed only in the IL23 group as early as at week 24 (p < 0.001). AIx75 was reduced significantly in the IL17 group at week 24 and in both IL-17 and IL-23 groups at week 52 (p < 0.001 and p = 0.014, respectively). The reduction of PWV and AIx75 at week 52 did not reach the level of statistical significance in the control group and was statistically comparable between the IL-17 and IL-23 groups.</p><p><strong>Conclusions: </strong>Both IL-23 and IL-17 inhibition exhibited comparable improvement of arterial stiffness in patients with psoriasis. Further studies are needed to evaluate the long-term impact of biologics on the cardiovascular status of these patients. Retrospectively registered ClinicalTrials.gov identifier: NCT07169682. A Graphical abstract is available for this article.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-10-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145250206","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Atopic Dermatitis and Climate: Environmental Stressors and Care Strategies.","authors":"Filomena Russo, Alexander Zink, Nina Magnolo, Enrico Scala, Emanuele Scala","doi":"10.1007/s13555-025-01560-6","DOIUrl":"https://doi.org/10.1007/s13555-025-01560-6","url":null,"abstract":"<p><p>Atopic dermatitis (AD) is a chronic inflammatory skin disorder with rising prevalence worldwide. Its pathogenesis involves a complex interplay between genetic predisposition, skin barrier dysfunction, and immune dysregulation. Environmental exposures, including allergens and pollutants, are well-recognized triggers of disease activity. Increasing attention is now being directed toward the role of climate, which may critically modulate AD onset and severity. This review examines climate-related stressors and their impact on AD, with a particular focus on extreme weather events, and outlines strategies for personalized management tailored to local climatic conditions.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":""},"PeriodicalIF":4.2,"publicationDate":"2025-10-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145244022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"JAK Inhibitors in Atopic Dermatitis: Does Weight Matter? A Real-World, Nationwide Retrospective Study: IL-AD (Italian Landscape Atopic Dermatitis).","authors":"Mariateresa Rossi, Stefano Bighetti, Alessandra Narcisi, Antonio Costanzo, Matteo Bianco, Piergiorgio Malagoli, Francesco Messina, Francesca Gaiani, Silvia Mariel Ferrucci, Angelo Valerio Marzano, Francesca Barei, Simone Ribero, Michela Ortoncelli, Francesco Leo, Maddalena Napolitano, Andrea Cosenza, Cataldo Patruno, Mario Bruno Guanti, Anna Balato, Francesco Loconsole, Claudio Sciarrone, Federica Veronese, Elena Pezzolo, Anna Graziella Burroni, Massimo Gola, Carlotta Gurioli, Flavia Manzo Margiotta, Maria Letizia Musumeci, Francesca Satolli, Giuseppe Amoruso, Maria Esposito, Caterina Foti, Paolo Pella, Anna Campanati, Andrea Carugno, Nicola Zerbinati, Martina Maurelli, Ilaria Trave, PierGiacomo Calzavara-Pinton, Luca Bettolini","doi":"10.1007/s13555-025-01477-0","DOIUrl":"10.1007/s13555-025-01477-0","url":null,"abstract":"<p><strong>Introduction: </strong>Janus kinase (JAK) inhibitors are effective systemic treatments for moderate-to-severe atopic dermatitis (AD), rapidly controlling symptoms and improving quality of life. However, the impact of body mass index (BMI) on therapeutic response remains unclear.</p><p><strong>Methods: </strong>This multicenter retrospective study analyzed data from 388 adult AD patients treated with upadacitinib, abrocitinib, or baricitinib across 25 Italian dermatology centers between May 2022 and July 2024. Patients were classified as overweight (BMI ≥ 25) or non-overweight (BMI < 25), with disease severity assessed using EASI, IGA, and Numerical Rating Scales (NRS) for pruritus and sleep disturbance over 104 weeks. The effect of different treatment dosages was also evaluated.</p><p><strong>Results: </strong>No significant BMI-related differences in clinical outcomes were noted at most timepoints. However, in the upadacitinib 15 mg group, non-overweight patients showed greater EASI and pruritus improvements at Week 4 (p = 0.037, p = 0.039), although these differences resolved subsequently. At Week 104, higher BMI modestly reduced EASI improvement (p = 0.045) in multivariable analysis.</p><p><strong>Conclusions: </strong>Treatment dosage consistently influenced clinical improvement regardless of BMI. These findings confirm the efficacy of JAK inhibitors across BMI categories, suggesting minimal short-term BMI influence but highlighting potential long-term considerations in overweight patients, emphasizing personalized dosing strategies and prolonged monitoring.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2833-2851"},"PeriodicalIF":4.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12454714/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144697779","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exploring the Experience of Black Americans Living with Hidradenitis Suppurativa in the United States Healthcare System: A Narrative Review.","authors":"Nicole A Negbenebor, Julia M Riley","doi":"10.1007/s13555-025-01496-x","DOIUrl":"10.1007/s13555-025-01496-x","url":null,"abstract":"<p><p>Black Americans face persistent healthcare disparities due to a combination of structural, socioeconomic, and historical factors, which can lead to disparities in healthcare quality access and health outcomes. Hidradenitis suppurativa (HS) is a chronic inflammatory disease that is associated with high physical, socioeconomic, and emotional burdens. HS is an example of the broader heath disparities faced by Black patients in the USA. The overall prevalence of HS in the USA is estimated to be 0.1-1.7%, but the prevalence is more than threefold higher among Black individuals than among White individuals. Black patients with HS often have more severe disease than White patients but face longer diagnostic delays and have less access to specialized dermatologic care. By addressing the barriers to care faced by Black patients with HS, dermatologists and healthcare providers can reduce health disparities and improve outcomes for these patients. The objective of this clinical review is to provide an overview of the disparities in clinical burden, diagnostic delays, and treatment faced by Black patients with HS. We also provide commentary from the physician's perspective on factors that contribute to these health disparities and approaches to reduce barriers to appropriate HS care.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2715-2727"},"PeriodicalIF":4.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12454235/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144728569","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"High-Frequency Ultrasound Imaging for Stage III Cellulite: A Three-Subtype Structural Classification from an Observational Cohort Study.","authors":"Dora Intagliata, Massimiliano Priolo, Paola Molinari","doi":"10.1007/s13555-025-01504-0","DOIUrl":"10.1007/s13555-025-01504-0","url":null,"abstract":"<p><strong>Introduction: </strong>Stage III cellulite is traditionally assessed through clinical inspection; however, visual scales often fail to capture the structural complexity of subcutaneous tissue. High-frequency ultrasound (HFUS) provides an objective, non-invasive method for visualizing the architecture of adipose tissue. This study aimed to develop and validate an ultrasound-based subclassification of stage III cellulite to improve diagnostic accuracy and facilitate personalized treatment strategies.</p><p><strong>Methods: </strong>This observational cohort study included 150 female patients (ages 20-55 years, BMI 18-32 kg/m²) with a clinical diagnosis of stage III cellulite. Two physicians independently performed clinical staging (3A/3B) using the Nürnberger-Müller scale. A single physician conducted HFUS examinations of the subgluteal and trochanteric regions using a 20-MHz probe. Ultrasound features, including fat thickness, echotexture, fibrosis, and edema, served to classify patients into three phenotypes: 3A, 3B, and mixed.</p><p><strong>Results: </strong>HFUS identified 50 patients in each subtype. The mean superficial fat thickness was 4.8 ± 1.1 mm in 3A, 11.3 ± 2.4 mm in 3B, and 8.6 ± 3.4 mm in mixed subtype. Severe fibrosis occurred in 100.0% of patients with type 3B, was absent in type 3A, and was variable in the mixed type. Edema was mild in all patients with type 3A (100.0%), severe in 44.0% of those with type 3B, and variable in the mixed group. Discrepancies between clinical and ultrasound classifications appeared in 33.3% of cases. Agreement between classifications was moderate (Gwet's AC1 = 0.444; p < 0.001).</p><p><strong>Conclusion: </strong>HFUS provides a valid and reproducible method for structurally assessing advanced cellulite. It enables the identification of a third, clinically unrecognized mixed phenotype, which has significant therapeutic implications by supporting more accurate treatment selection and improving treatment personalization.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2865-2878"},"PeriodicalIF":4.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12454704/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144728570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-World Effectiveness and Safety of Risankizumab in Psoriasis: A Comprehensive Analysis from the Saudi Arabia Psoriasis Registry (PSORSA).","authors":"Mohammed Ibrahim Fatani, Abdulaziz Madani, Fahad Alzuriqan, Abdullah Albadri, Ahmed Aljedai, Hajer Almudaiheem, Maysa Tariq Eshmawi","doi":"10.1007/s13555-025-01493-0","DOIUrl":"10.1007/s13555-025-01493-0","url":null,"abstract":"<p><strong>Introduction: </strong>Psoriasis is a chronic immune-mediated skin condition that has a substantial impact on patients' quality of life. The Saudi Arabia Psoriasis Registry (PSORSA) was established to address long-term real-world data (RWD) on systemic and biologic therapies in the region. This observational cohort study provides a comprehensive analysis of baseline disease characteristics, comorbidities, and treatment efficacy among patients enrolled in PSORSA, with an emphasis on risankizumab.</p><p><strong>Methods: </strong>Data were sourced from a governmental online database covering multiple healthcare centers. Patients eligible for biologics were followed at baseline and at weeks 16, 28, 40, and 52 to evaluate disease severity, quality of life, and adherence. Statistical analyses were conducted using Jamovi and R. Descriptive statistics were performed for categorical and continuous variables. p-Values < 0.05 were considered significant.</p><p><strong>Results: </strong>The study cohort included 313 patients. Plaque psoriasis was the most prevalent clinical type (93.9%). An analysis of treatment history revealed that 39.6% of patients had prior therapy exposure, and all patients received risankizumab as a biologic therapy. At baseline, the mean Psoriasis Area and Severity Index (PASI) score was 25.49. By week 52, it had decreased to 0.358, indicating complete clearance. PASI scores showed a steady and substantial reduction over time, with an 88% reduction at week 16, 96% at week 28, 97.5% at week 40, and 98.5% by week 52, demonstrating a strong and sustained treatment effect (p < 0.001). Additionally, risankizumab exhibited a favorable drug survival profile, with many patients maintaining treatment beyond 122 weeks.</p><p><strong>Conclusion: </strong>This study represents the first real-world assessment of risankizumab for moderate-to-severe psoriasis in Saudi Arabia. The findings demonstrate that risankizumab is an effective and well-tolerated treatment for moderate-to-severe psoriasis in this Saudi Arabian cohort. However, future studies should explore long-term safety outcomes and the comparative effectiveness of risankizumab and emerging biologics in diverse patient populations.</p>","PeriodicalId":11186,"journal":{"name":"Dermatology and Therapy","volume":" ","pages":"2853-2864"},"PeriodicalIF":4.2,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12454820/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144706701","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}